Nextbiomedical Co

Nexpowder is a powdered endoscopy hemostatic agent made of biocompatible polymers. It forms a gel upon contact with blood or moisture, physically compressing wounds to stop or prevent bleeding regardless of location.

NextBiomedical’s stock rises 10% after announcing an exclusive distribution partnership with Asahi Intecc, a Japanese medical device firm. The agreement secures NextBiomedical’s entry into the Japanese market through Asahi Intecc’s global distribution network. Early trading on April 10 reflects investor optimism over the strategic collaboration.

Apr 2026Seoul Economic DailyNews article

NEXTBIOMEDICAL partners with Asahi Intecc for exclusive distribution of its fast-resorbable microsphere, Nexsphere-F™, in Japan. The agreement expands market access for the embolization device, leveraging Asahi Intecc’s global medical device network. Nexsphere-F™ is designed for targeted vascular treatments, offering rapid absorption properties.

Apr 2026PR NewswireNews article

NEXTBIOMEDICAL enrolls the first patient in a U.S. FDA pivotal trial for **Nexsphere-F™**, its fast-resorbable microsphere treatment designed to address knee osteoarthritis pain. The trial marks a key step in the company’s U.S. regulatory approval process, following FDA clearance for its Investigational Device Exemption (IDE). Nexsphere-F™ targets musculoskeletal pain through embolization, a minimally invasive procedure.

Oct 2025PR NewswireNews article

Next Biomedical delivers its hemostatic powder **Nexpowder** to Japan for endoscopic treatment of gastrointestinal bleeding. The product, approved by Japan’s **Pharmaceuticals and Medical Devices Agency (PMDA)**, stops bleeding by applying powder directly to wounds in the stomach and colon. Nexpowder aims to prevent recurrent bleeding during endoscopic procedures.

Mar 2025ChosunbizNews article